Ambrisentan Tablet, Film Coated
Product Images NDC 59651-494

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Ambrisentan (NDC 59651-494). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ambrisentan-fig1.jpg (Ambrisentan Fig1)

Ambrisentan-fig1.jpg (Ambrisentan Fig1)
This appears to be a chart showing the interaction of various drugs with ambrisentan, with information on fold change and recommended dosage adjustments. The drugs listed include cyclosporine, mycophenolate moetal, ketoconazole, omeprazole, rifampin, tacrolimus, tadalafil, and warfarin. The chart also includes information on various pharmacokinetic parameters such as Cmax and Auc.*
FDA Label Image

Ambrisentan-fig2.jpg (Ambrisentan Fig2)

Ambrisentan-fig2.jpg (Ambrisentan Fig2)
This is a list of drugs that interact with each other along with the recommended dose for each drug. There are no required dose adjustments for any of the drugs on this list. PK and Emax values are also listed.*
FDA Label Image

Ambrisentan-fig3.jpg (Ambrisentan Fig3)

FDA Label Image

Ambrisentan-fig4.jpg (Ambrisentan Fig4)

Ambrisentan-fig4.jpg (Ambrisentan Fig4)
This is a clinical trial study named ARIES that compares the effects of Ambrisentan and Placebo on a group of individuals at different time intervals (ARIES-1 and ARIES-2). The data represents the number of individuals at risk, percentage of individuals with a certain outcome and the time frame measured in weeks. It is not possible to infer further information from this text due to the lack of context and extensive errors.*
FDA Label Image

Figure 6 (Ambrisentan Fig5)

FDA Label Image

Package Label-principal Display Panel (5 mg Container Label (30 Tablets Bottle))

Package Label-principal Display Panel (5 mg Container Label (30 Tablets Bottle))
Ambrisentan Tablets are a prescription drug that contains 5mg of ambrisentan in each film-coated tablet. Pharmacists are advised to provide the medication guide to each patient. The tablet should not be split, crushed, or chewed. The medication should be stored at 20-25°C (68-77°F), but excursions are allowed to 15-30°C. Dispense in the original container and keep it tightly closed. Medication guides can be printed at www.aurobindousa.com/medication-guides. This drug is supplied by Aurobindo Pharma USA, Inc. and is made in India.*
FDA Label Image

Package Label-principal Display Panel (10 mg Container Label (30 Tablets Bottle))

Package Label-principal Display Panel (10 mg Container Label (30 Tablets Bottle))
Ambrisentan Tablets are prescribed medication that should be dispensed with a Medication Guide provided separately for each patient. Each package contains thirty film-coated tablets, and the usual dosage is ten milligrams per tablet. The tablets should not be split, crushed, or chewed, and must be stored between 20° to 25°C (68° to 77°F), with an permitted excursion of 15° to 30°C (59° to 86°F). The medication should only be dispensed in the original container, and further guidance should be obtained from the package insert. The medication is distributed by Aurobindo Pharma USA, Inc., and further details can be found at www.aurobindousa.com/medication-quides.*
FDA Label Image

Ambrisentan-str.jpg (Ambrisentan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.